S. Pastorino

Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer.

M. Venturini, Paolo Bruzzi, Lucia Del Mastro et al. · Journal of Clinical Oncology · 1996 · 51 citations

Medicine, Oncology, Pharmacology +17

Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial

Lucia Del Mastro, Francesca Poggio, Eva Blondeaux et al. · The Lancet Oncology · 2022 · 50 citations

Medicine, Oncology, Pharmacology +12

Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy as a strategy to reduce ovarian failure in early breast cancer patients

Matteo Lambertini, Luca Boni, Andrea Michelotti et al. · Annals of Oncology · 2015 · 32 citations

Medicine, Oncology, Pharmacology +13

First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients

Antonella Romanini, L Tanganelli, F Carnino et al. · Gynecologic Oncology · 2003 · 23 citations

Medicine, Oncology, Pharmacology +11

Abstract S5-06: Epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) versus fluorouracil, epirubicin and cyclophosphamide (FEC) followed by T, all given every 3 weeks or 2 weeks, in node-positive early breast cancer (BC) patients (pts). Final results of the gruppo Italiano mammella (GIM)-2 randomized phase III study

Francesco Cognetti, Paolo Bruzzi, Sabino De Placido et al. · Cancer Research · 2013 · 11 citations

Medicine, Oncology, Pharmacology +13